{"id":"vaccination","rwe":[],"_fda":{"id":"960fab85-6ea8-4799-bcd8-ac46fad57822","set_id":"a7a262f1-fe38-4e6b-aefa-f9e8a914f38e","openfda":{"nui":["N0000183898","N0000183364","M0361653","M0023305","N0000183917","M0019978","M0569003"],"unii":["DL6OZ476V3","YHA2XLJ956","T7S323PKJS","324Y4038G2","0LVY784C09","KF7Z0E0Q2B","ETJ7Z6XBU4","70FD1KFU70","0T0DQN8786","4SV59689SK"],"route":["ORAL"],"spl_id":["960fab85-6ea8-4799-bcd8-ac46fad57822"],"brand_name":["Childhood Vaccination Nosode Combination 9409"],"spl_set_id":["a7a262f1-fe38-4e6b-aefa-f9e8a914f38e"],"package_ndc":["63083-9409-1"],"product_ndc":["63083-9409"],"generic_name":["CHILDHOOD VACCINATION NOSODE COMBINATION"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Poliovirus Vaccines [CS]","Vaccines, Inactivated [CS]","Smallpox Vaccine [CS]","Vaccines, Live, Unattenuated [CS]"],"pharm_class_pe":["Actively Acquired Immunity [PE]"],"substance_name":["ANTIMONY POTASSIUM TARTRATE","CROTALUS HORRIDUS HORRIDUS VENOM","HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK","MERCURIUS SOLUBILIS","POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)","QUININE SULFATE","SILICON DIOXIDE","SULFUR","THUJA OCCIDENTALIS LEAF","VACCINIA VIRUS STRAIN NEW YORK CITY BOARD OF HEALTH LIVE ANTIGEN"],"pharm_class_epc":["Inactivated Poliovirus Vaccine [EPC]","Live Vaccinia Virus Vaccine [EPC]"],"manufacturer_name":["Professional Complementary Health Formulas"],"is_original_packager":[true]},"purpose":["*Claims based on traditional homeopathic practice, not accepted medical evidence. Not FDA evaluated."],"version":"2","warnings":["WARNINGS Persistent symptoms may be a sign of a serious condition. If symptoms persist or are accompanied by a fever, rash, or persistent headache, consult a doctor. Keep out of the reach of children. In case of overdose, get medical help or contact a poison control center right away. If pregnant or breastfeeding, ask a healthcare professional before use. Keep out of the reach of children. If pregnant or breastfeeding, ask a healthcare professional before use."],"questions":["QUESTIONS Professional Formulas PO Box 2034 Lake Oswego, OR 97035"],"effective_time":"20260108","active_ingredient":["ACTIVE INGREDIENTS Antimonium tartaricum 6X Hamamelis virginiana 6X Chininum sulphuricum 8X Sulphur 8X Crotalus horridus 10X Mercurius solubilis 12X Poliomyelitis 12X Silicea 12X Thuja occidentalis 12X Vaccinotoxinum 12X"],"inactive_ingredient":["INACTIVE INGREDIENTS 40% ethanol, purified water."],"indications_and_usage":["INDICATIONS For the temporary relief of occasional headache, minor muscle or joint pain, fatigue, nausea or vomiting, diarrhea, or constipation.*"],"other_safety_information":["OTHER INFORMATION Tamper resistant. If seal is broken, do not use. After opening, close container tightly and store at room temperature away from heat."],"dosage_and_administration":["DIRECTIONS Place drops under tongue 30 minutes before/after meals. Adults and children 12 years and over: Take 10 to 15 drops once weekly or monthly. If mild symptoms are present, take 10 drops up to 3 times per day. Consult a physician for use in children under 12 years of age."],"spl_product_data_elements":["Childhood Vaccination Nosode Combination 9409 Childhood Vaccination Nosode Combination ANTIMONY POTASSIUM TARTRATE ANTIMONY CATION (3+) HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK HAMAMELIS VIRGINIANA ROOT BARK/STEM BARK QUININE SULFATE QUININE SULFUR SULFUR CROTALUS HORRIDUS HORRIDUS VENOM CROTALUS HORRIDUS HORRIDUS VENOM MERCURIUS SOLUBILIS MERCURIUS SOLUBILIS POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED) POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED) SILICON DIOXIDE SILICON DIOXIDE THUJA OCCIDENTALIS LEAF THUJA OCCIDENTALIS LEAF VACCINIA VIRUS STRAIN NEW YORK CITY BOARD OF HEALTH LIVE ANTIGEN VACCINIA VIRUS STRAIN NEW YORK CITY BOARD OF HEALTH LIVE ANTIGEN ALCOHOL WATER"],"pregnancy_or_breast_feeding":["If pregnant or breastfeeding, ask a healthcare professional before use."],"keep_out_of_reach_of_children":["Keep out of the reach of children."],"package_label_principal_display_panel":["LABEL Est 1985 Professional Formulas Complementary Health Childhood Vaccination Nosode Combination Homeopathic Remedy 1 FL. OZ. (29.5 mL) Label image"]},"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"Reported 26 times"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"Reported 26 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 24 times"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"Reported 21 times"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"Reported 18 times"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"Reported 17 times"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"Reported 16 times"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"Reported 15 times"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"Reported 15 times"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"Reported 15 times"}],"drugInteractions":[{"drug":"Live Attenuated Vaccines","action":"Avoid","effect":"Decreased immune response"},{"drug":"Immunosuppressants","action":"Avoid","effect":"Decreased immune response"},{"drug":"Interferons","action":"Avoid","effect":"Decreased immune response"},{"drug":"Corticosteroids","action":"Avoid","effect":"Decreased immune response"},{"drug":"Antibiotics","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Antivirals","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Antifungals","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Antihistamines","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Anticholinergics","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Sedatives","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Anesthetics","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Cancer Chemotherapy","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Radiation Therapy","action":"Monitor","effect":"Decreased effectiveness"},{"drug":"Immunoglobulins","action":"Avoid","effect":"Decreased effectiveness"},{"drug":"Blood Transfusions","action":"Avoid","effect":"Decreased effectiveness"},{"drug":"Interleukins","action":"Avoid","effect":"Decreased effectiveness"},{"drug":"Colony-Stimulating Factors","action":"Avoid","effect":"Decreased effectiveness"}],"commonSideEffects":[],"contraindications":["Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely immunocompromised)","Pregnancy","Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component","Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days after administration of a previous dose of pertussis-containing vaccine","Severe Combined Immunodeficiency (SCID) disease","History of intussusception","Guillain-Barré Syndrome (GBS) <6 weeks after previous dose of tetanus-toxoid–containing vaccine","History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid—containing vaccine"],"specialPopulations":{"Pregnancy":"Immunization is an essential part of preventive care for adults, including pregnant individuals. Each vaccine recommended for pregnant patients is important for the protection of the maternal–child dyad. Other vaccines provide maternal protection from severe morbidity related to specific pathogens such as pneumococcus, meningococcus, and hepatitis for at-risk pregnant individuals. Obstetrician–gynecologists and other obstetric care professionals should routinely assess their pregnant patients' immunization status and provide recommended vaccines. Individuals who are or will be pregnant during the fall/winter respiratory illness season should receive annual influenza and coronavirus disease 2019 (COVID-19) vaccines. All pregnant individuals should receive a Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine during each pregnancy, as early in the 27–36 gestational-week window as possible. All eligible pregnant individuals who meet criteria should receive the respiratory syncytial virus (RSV) vaccine. Other vaccines may be recommended during pregnancy depending on the patient's age, prior immunizations, comorbidities, etc.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_whoEML":{"listed":true,"source":"WHO EML"},"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=vaccination","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:30:50.017159+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Vaccination","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:30:57.970191+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:30:55.985280+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:30:50.089751+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vaccination","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:30:56.679724+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:30:48.752704+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:30:48.752732+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:30:48.752737+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107962/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:30:57.618943+00:00"}},"allNames":"post - vaccination","offLabel":[],"timeline":[{"date":"10th century","type":"neutral","_source":"Wikipedia","milestone":"Variolation for smallpox in China","regulator":"none"},{"date":"1549","type":"neutral","_source":"Wikipedia","milestone":"Oldest documented use of variolation","regulator":"none"},{"date":"1700","type":"neutral","_source":"Wikipedia","milestone":"Reports on Chinese practice of inoculation received by Royal Society","regulator":"none"},{"date":"1796","type":"neutral","_source":"Wikipedia","milestone":"Edward Jenner's work","regulator":"none"}],"_dailymed":{"setId":"a7a262f1-fe38-4e6b-aefa-f9e8a914f38e","title":"CHILDHOOD VACCINATION NOSODE COMBINATION 9409 (CHILDHOOD VACCINATION NOSODE COMBINATION) LIQUID [PROFESSIONAL COMPLEMENTARY HEALTH FORMULAS]","labeler":""},"aiSummary":"Pfizer's vaccination drug is a vaccine that helps the immune system develop immunity from diseases. It contains a weakened or killed virus or microorganism. The key indications include viral-related symptoms, injection site pain, fever, inflammation, and fatigue. This drug is marketed and has a large number of trials and publications. It is a first-in-class vaccine that provides herd immunity and protects immunocompromised individuals. The commercial significance of this drug is its ability to prevent infectious diseases. Pfizer's vaccination drug is a significant development in the pharma industry.","brandName":"Post - Vaccination","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Immune system","novelty":"First-in-class","modality":"Vaccine","drugClass":"Inactivated Poliovirus Vaccine [EPC]","explanation":"","oneSentence":"","technicalDetail":"The vaccine stimulates the body's adaptive immunity by introducing a specific antigen that triggers the production of antibodies. This process involves the activation of immune cells, such as T-cells and B-cells, which recognize and respond to the antigen. The resulting immune response provides long-term protection against the disease."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Vaccination","extract":"Vaccination is the administration of a vaccine to help the immune system develop immunity from a disease. Vaccines contain a microorganism or virus in a weakened, live or killed state, or proteins or toxins from the organism. In stimulating the body's adaptive immunity, they help prevent sickness from an infectious disease. When a sufficiently large percentage of a population has been vaccinated, herd immunity results. Herd immunity protects those who may be immunocompromised and cannot get a vaccine because even a weakened version would harm them.","wiki_history":"==History==\n\nthumb|upright=0.8|An 1802 testimonial to the efficacy of vaccination, presented to its pioneer, [[Edward Jenner, and signed by 112 members of the Physical Society, London]]\n\nThe earliest hints of the practice of variolation for smallpox in China date back to the 10th century. The oldest documented use of variolation comes from Wan Quan's Douzhen Xinfa (痘疹心法), published in 1549. They implemented a method of \"nasal insufflation\" administered by blowing powdered smallpox material, usually scabs, up the nostrils. Various insufflation techniques have been recorded throughout the sixteenth and seventeenth centuries within China. Two reports on the Chinese practice of inoculation were received by the Royal Society in London in 1700; one by Martin Lister who received a report by an employee of the East India Company stationed in China and another by Clopton Havers. In France, Voltaire reports that the Chinese have practiced variolation \"these hundred years\".\n\nIn 1796, Edward Jenner, a doctor in Berkeley in Gloucestershire, England, tested a common theory that a person who had contracted cowpox would be immune from smallpox. To test the theory, he took cowpox vesicles from a milkmaid named Sarah Nelmes, with which he infected an eight-year-old boy named James Phipps. Two months later he inoculated the boy with smallpox, and smallpox did not develop. In 1798, Jenner published An Inquiry Into the Causes and Effects of the Variolæ Vaccinæ which created widespread interest. H"},"commercial":{"annualCostUS":"","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":""},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=vaccination","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=vaccination","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=vaccination","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://en.wikipedia.org/wiki/vaccination","fields":["history","overview"],"source":"Wikipedia"},{"id":6,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":7,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":8,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:27.725637+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Allergies","slug":"apis-mellifica-echinacea-hydrastis-canadensis-taraxacum-officinale-aconitum-napellus-aethusa-cynapium-agaricus-muscarius-aletris-farinosa-alfalfa-allium-cepa-allium-sativum-ambrosia-artemisiaefolia-arsenicum-album-artemisia-vulgaris-arundo-mauritanica-avena-sativa-belladonna-bellis-perrenis-bovista-bromium-bryonia-caffeinum-calcarea-carbonica-calluna-vulgaris-flos-capsicum-annuum-cat-hair-chamomilla-chelidonium-majus-chenopodium-anthelminticum-cinnamomum","company":"Newton Laboratories, Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"APIS MELLIFICA, ECHINACEA, HYDRASTIS CANADENSIS, TARAXACUM OFFICINALE, ACONITUM NAPELLUS, AETHUSA CYNAPIUM, AGARICUS MUSCARIUS, ALETRIS FARINOSA, ALFALFA, ALLIUM CEPA, ALLIUM SATIVUM, AMBROSIA ARTEMISIAEFOLIA, ARSENICUM ALBUM, ARTEMISIA VULGARIS, ARUNDO MAURITANICA, AVENA SATIVA, BELLADONNA, BELLIS PERRENIS, BOVISTA, BROMIUM, BRYONIA, CAFFEINUM, CALCAREA CARBONICA, CALLUNA VULGARIS, FLOS, CAPSICUM ANNUUM, CAT HAIR, CHAMOMILLA, CHELIDONIUM MAJUS, CHENOPODIUM ANTHELMINTICUM, CINNAMOMUM"},{"name":"Pollen Distress","slug":"allium-cepa-apis-mellifica-aralia-racemosa-arundo-mauritanica-baptisia-tinctoria-echinacea-(angustifolia)-euphrasia-officinalis-gelsemium-sempervirens-histaminum-hydrochloricum-lycopodium-clavatum-rhus-tox-sabadilla-sanguinaria-canadensis-urtica-urens","company":"Liddell Laboratories, Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"ALLIUM CEPA, APIS MELLIFICA, ARALIA RACEMOSA, ARUNDO MAURITANICA, BAPTISIA TINCTORIA, ECHINACEA (ANGUSTIFOLIA), EUPHRASIA OFFICINALIS, GELSEMIUM SEMPERVIRENS, HISTAMINUM HYDROCHLORICUM, LYCOPODIUM CLAVATUM, RHUS TOX, SABADILLA, SANGUINARIA CANADENSIS, URTICA URENS"},{"name":"Blue Scorpion Pain and Inflammation Relief","slug":"heteroctenus-princeps-venom-apis-mellifica-rhus-toxicodendron","company":"Blue Scorpion Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"HETEROCTENUS PRINCEPS VENOM, APIS MELLIFICA, RHUS TOXICODENDRON"},{"name":"B HP","slug":"apis-mellifica-arsenicum-album-belladonna-chamomilla-echinacea-(angustifolia)-lachesis-mutus-mercurius-solubilis-pulsatilla-(pratensis)-pyrogenium-rhus-tox-silicea","company":"Energique, Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"APIS MELLIFICA, ARSENICUM ALBUM, BELLADONNA, CHAMOMILLA, ECHINACEA (ANGUSTIFOLIA), LACHESIS MUTUS, MERCURIUS SOLUBILIS, PULSATILLA (PRATENSIS), PYROGENIUM, RHUS TOX, SILICEA"},{"name":"Clearlife Extra Strength","slug":"onion-ambrosia-artemisiifolia-whole-apis-mellifera-arnica-montana-whole-euphrasia-stricta-graphitegalphimia-glauca-flowering-toppulsatilla-vulgaris-whole-histamine-dihydrochloride-pine-tar-schoenocaulon-officinale-seed-sulfur-sulfuric-acidtellurium-and-thuja-occidentalis-leafy-twig","company":"MediNatura Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"ONION, AMBROSIA ARTEMISIIFOLIA WHOLE, APIS MELLIFERA, ARNICA MONTANA WHOLE, EUPHRASIA STRICTA, GRAPHITE,GALPHIMIA GLAUCA FLOWERING TOP,PULSATILLA VULGARIS WHOLE, HISTAMINE DIHYDROCHLORIDE, PINE TAR, SCHOENOCAULON OFFICINALE SEED, SULFUR, SULFURIC ACID,TELLURIUM AND THUJA OCCIDENTALIS LEAFY TWIG"},{"name":"Bladder Kidney Meridian Opener","slug":"apis-mellifica-argentum-nitricum-berberis-vulgaris-cantharis-equisetum-arvense-kali-bichromicum-lycopodium-clavatum-mercurius-solubilis-natrum-muriaticum-phosphorus-rhus-tox-sepia-terebinthina-thuja-occidentalis","company":"Deseret Biologicals, Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"APIS MELLIFICA, ARGENTUM NITRICUM, BERBERIS VULGARIS, CANTHARIS, EQUISETUM ARVENSE, KALI BICHROMICUM, LYCOPODIUM CLAVATUM, MERCURIUS SOLUBILIS, NATRUM MURIATICUM, PHOSPHORUS, RHUS TOX, SEPIA, TEREBINTHINA, THUJA OCCIDENTALIS"},{"name":"Female Tonic","slug":"condurango-humulus-lupulus-agnus-castus-caulophyllum-thalictroides-iris-versicolor-lilium-tigrinum-asterias-rubens-apis-mellifica-calcarea-fluorica-conium-maculatum-ignatia-amara-lac-caninum-lachesis-mutus-sepia-cyclamen-europaeum","company":"BioActive Nutritional, Inc.","advantage":"Same class (Standardized Insect Venom Allergenic Extract [EPC])","genericName":"CONDURANGO, HUMULUS LUPULUS, AGNUS CASTUS, CAULOPHYLLUM THALICTROIDES, IRIS VERSICOLOR, LILIUM TIGRINUM, ASTERIAS RUBENS, APIS MELLIFICA, CALCAREA FLUORICA, CONIUM MACULATUM, IGNATIA AMARA, LAC CANINUM, LACHESIS MUTUS, SEPIA CYCLAMEN EUROPAEUM"}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"vaccination","indications":{"approved":[{"name":"viral-related symptoms","regulator":"FDA"},{"name":"injection site pain","regulator":"FDA"},{"name":"fever","regulator":"FDA"},{"name":"inflammation","regulator":"FDA"},{"name":"fatigue","regulator":"FDA"},{"name":"skin discomfort","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT04967807","phase":"NA","title":"Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-08-05","conditions":"Myocardial Injury, Myocarditis, COVID-19 Vaccination","enrollment":57},{"nctId":"NCT05652504","phase":"PHASE1","title":"Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Malaria","enrollment":400},{"nctId":"NCT05988203","phase":"PHASE1, PHASE2","title":"A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-09-21","conditions":"Monkeypox","enrollment":96},{"nctId":"NCT07407569","phase":"PHASE2","title":"Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2026-03-25","conditions":"Human Papilloma Virus Infection Type 16","enrollment":50},{"nctId":"NCT04304768","phase":"PHASE4","title":"Opioid, HIV and Immune System","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-11-18","conditions":"Immune Defect","enrollment":400},{"nctId":"NCT06551506","phase":"PHASE4","title":"The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-19","conditions":"Respiratory Syncytial Virus Infection","enrollment":181},{"nctId":"NCT03971669","phase":"PHASE4","title":"Blood Donor CVD 5000","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2004-01-16","conditions":"Risk Reduction","enrollment":150},{"nctId":"NCT03387553","phase":"EARLY_PHASE1","title":"HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-06-06","conditions":"Breast Cancer, Breast Cancer Female, Breast Cancer, Male","enrollment":31},{"nctId":"NCT05642195","phase":"PHASE1, PHASE2","title":"Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT04235816","phase":"PHASE3","title":"Improving Care Through Azithromycin Research for Infants in Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2021-03-15","conditions":"Child Mortality","enrollment":20560},{"nctId":"NCT03328026","phase":"PHASE1, PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":"Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer","enrollment":36},{"nctId":"NCT07495124","phase":"PHASE2","title":"IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma","enrollment":26},{"nctId":"NCT07498075","phase":"NA","title":"A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-01","conditions":"HPV, HPV Vaccine","enrollment":3340},{"nctId":"NCT07248904","phase":"NA","title":"The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions","status":"RECRUITING","sponsor":"Cukurova University","startDate":"2026-01-16","conditions":"Human Papillomavirus (HPV), Papillomavirus Vaccines, Health Knowledge, Attitudes, Practice","enrollment":88},{"nctId":"NCT01915212","phase":"PHASE1","title":"Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-09-26","conditions":"Healthy Volunteers","enrollment":69},{"nctId":"NCT07251465","phase":"","title":"A Study to Learn How Effective is PCV20 to Help Stop Adults Who Have a Higher Chance of Getting Pneumonia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2026-01-21","conditions":"Pneumonia","enrollment":846279},{"nctId":"NCT06735209","phase":"PHASE1","title":"First-in-Human PfSPZ-LARC2 Vaccination/CHMI","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-23","conditions":"Malaria","enrollment":22},{"nctId":"NCT05985681","phase":"PHASE1","title":"Testing RG1-VLP Vaccine to Prevent HPV-related Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-27","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":18},{"nctId":"NCT04801147","phase":"PHASE1, PHASE2","title":"Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2010-06-26","conditions":"Glioblastoma","enrollment":76},{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT05680948","phase":"","title":"Extended Follow-Up of the ISS T-003 Trial Volunteers (ISS T-003 EF-UP2020)","status":"COMPLETED","sponsor":"Istituto Superiore di Sanità","startDate":"2023-01-25","conditions":"HIV Infections","enrollment":179},{"nctId":"NCT07341191","phase":"PHASE2","title":"Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-31","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT07492303","phase":"PHASE1","title":"A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine (For Adults and Adolescents)","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2026-04-20","conditions":"Pertussis (Whooping Cough), Diphtheria, Tetanus","enrollment":96},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06482905","phase":"PHASE1","title":"Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.","status":"RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2024-09-04","conditions":"High-grade Glioma, WHO Grade Ⅳ Glioma","enrollment":52},{"nctId":"NCT05385042","phase":"NA","title":"Iron and Immune Response to Vaccine (IRONMUM)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-06-18","conditions":"Pregnancy Related","enrollment":171},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT01191853","phase":"","title":"Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-18","conditions":"Healthy Volunteers, Influenza","enrollment":203},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07489989","phase":"PHASE2","title":"Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-05-15","conditions":"Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)","enrollment":30},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":"Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT06862453","phase":"PHASE1","title":"Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults","status":"NOT_YET_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2026-03","conditions":"Malaria Falciparum","enrollment":58},{"nctId":"NCT07488962","phase":"NA","title":"Building Cognitive Resilience to Vaccine Misinformation Using AI: Evidence From a Randomised Trial","status":"NOT_YET_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2026-03","conditions":"Healthy","enrollment":1000},{"nctId":"NCT07042074","phase":"NA","title":"Use of Augmented Reality and Virtual Reality During Cognitive Behavioral Therapy for Needle Phobia","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-05-01","conditions":"Needle Phobia, Virtual Reality, Cognitive Behavior Treatment","enrollment":20},{"nctId":"NCT07487077","phase":"PHASE4","title":"Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya","status":"RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-10-31","conditions":"Cholera Vaccination","enrollment":1071},{"nctId":"NCT07488520","phase":"PHASE4","title":"Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire","status":"NOT_YET_RECRUITING","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2026-04","conditions":"Sickle Cell Disease (SCD)","enrollment":120},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06738355","phase":"NA","title":"PREVENT Pilot HPV - Related Cancers Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2025-05-20","conditions":"HPV Vaccination, Uptake Vaccination, Series Completion","enrollment":335},{"nctId":"NCT07485283","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia","status":"NOT_YET_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2026-03","conditions":"Cardiovascular Disease, Dementia","enrollment":162000},{"nctId":"NCT06652737","phase":"PHASE1","title":"Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanaria Inc.","startDate":"2025-03-04","conditions":"Malaria Falciparum, Malaria Infection","enrollment":75},{"nctId":"NCT06976632","phase":"NA","title":"Effect of Helfer Skin Tap and Cold Application on Pain and Hemodynamics During Vaccination","status":"RECRUITING","sponsor":"Celal Bayar University","startDate":"2025-05-09","conditions":"Pregnant Women","enrollment":90},{"nctId":"NCT05313139","phase":"","title":"Surveillance of Vaccine-induced Immunity Against Ebola in Previously Vaccinated Health Care Workers","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-12-13","conditions":"Immune Response","enrollment":133},{"nctId":"NCT05796193","phase":"NA","title":"Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-10-02","conditions":"Malaria","enrollment":1650},{"nctId":"NCT04779827","phase":"NA","title":"Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-05-04","conditions":"Vaccination Refusal, Covid19, Heart Diseases","enrollment":4476},{"nctId":"NCT05879965","phase":"","title":"Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-10-06","conditions":"Monkeypox","enrollment":345},{"nctId":"NCT06719219","phase":"PHASE1","title":"A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2025-01-07","conditions":"Staphylococcus (S.) Aureus Infection","enrollment":129},{"nctId":"NCT06866405","phase":"PHASE3","title":"A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"RSV Infection","enrollment":550},{"nctId":"NCT06658405","phase":"PHASE2","title":"Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2025-01-13","conditions":"Cervical Lesion","enrollment":85},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT06833957","phase":"","title":"Preparing for Maternal GBS Vaccine Trials in Africa","status":"RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2025-03-01","conditions":"Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization","enrollment":18100},{"nctId":"NCT07083479","phase":"","title":"Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma","status":"AVAILABLE","sponsor":"Elicio Therapeutics","startDate":"","conditions":"Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V","enrollment":""},{"nctId":"NCT05726864","phase":"PHASE1, PHASE2","title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elicio Therapeutics","startDate":"2023-04-14","conditions":"Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D","enrollment":158},{"nctId":"NCT05500482","phase":"PHASE4","title":"Vellore Typhoid Vaccine Impact Trial","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2023-05-01","conditions":"Typhoid Fever","enrollment":72400},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT05846516","phase":"PHASE1","title":"A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2023-05-11","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":58},{"nctId":"NCT06927297","phase":"PHASE1","title":"Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-05-09","conditions":"Advanced Solid Tumor Malignancies, Advanced Solid Malignancies","enrollment":12},{"nctId":"NCT06256718","phase":"NA","title":"Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-05-24","conditions":"Human Papillomavirus Infection","enrollment":203},{"nctId":"NCT06736977","phase":"NA","title":"Effectiveness of Nurse-Led Education Programmes to Enhance Infection Prevention and Control Among Childcare Workers in Bangkok Daycare Centres, Thailand","status":"COMPLETED","sponsor":"Universiti Putra Malaysia","startDate":"2025-02-01","conditions":"Hand Hygiene Behavior, Infection Control, Infection Prevention","enrollment":180},{"nctId":"NCT07158814","phase":"PHASE4","title":"Safety of RSV Preventive Monoclonal Antibody","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-10-02","conditions":"Fever, Adverse Event Following Immunisation","enrollment":524},{"nctId":"NCT06992141","phase":"EARLY_PHASE1","title":"A Strep Throat Controlled Human Infection Trial in Healthy Adults","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2025-07-24","conditions":"Streptococcus Pyogenes Pharyngitis, Streptococcus Infection","enrollment":40},{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT02200276","phase":"NA","title":"Influenza Immunization in Adults Over Age 75","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2014-03","conditions":"Influenza, Immunization, Older Adults","enrollment":1025},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT06784726","phase":"PHASE2","title":"Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-09-04","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":27},{"nctId":"NCT00820820","phase":"NA","title":"IDA (Immunothérapie de la Dermatite Atopique) Adult - Immunotherapy in Atopic Dermatitis","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-01-09","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT04936529","phase":"PHASE2","title":"A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-08-02","conditions":"Neuroblastoma","enrollment":286},{"nctId":"NCT06926062","phase":"NA","title":"Interpersonal Communication Training and Vaccination Workflow Training Alone and in Combination to Improve Communication and Recommendations About HPV Vaccination in Pharmacies, IMPACT HPV Trial","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-06-01","conditions":"Human Papillomavirus-Related Carcinoma","enrollment":1900},{"nctId":"NCT07463781","phase":"","title":"Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2026-05","conditions":"Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL)","enrollment":100},{"nctId":"NCT02316457","phase":"PHASE1","title":"RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2016-10","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":42},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07471906","phase":"","title":"Compliance to Vaccination in Children With Diabetes and Their Siblings","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2019-11-01","conditions":"Type 1 Diabetes","enrollment":60},{"nctId":"NCT06688058","phase":"PHASE1","title":"A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-20","conditions":"Healthy","enrollment":72},{"nctId":"NCT03943875","phase":"PHASE4","title":"GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2019-06-17","conditions":"Immunization, Efficacy, Human Papilloma Virus","enrollment":767},{"nctId":"NCT02287428","phase":"PHASE1","title":"Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-11","conditions":"Glioblastoma","enrollment":56},{"nctId":"NCT06181292","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2023-11-15","conditions":"SARS-CoV2 Infection","enrollment":913},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT02410733","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2015-03","conditions":"Melanoma","enrollment":119},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT05142553","phase":"PHASE2","title":"Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.","status":"COMPLETED","sponsor":"Hipra Scientific, S.L.U","startDate":"2021-11-16","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":887},{"nctId":"NCT07280741","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2025-12-02","conditions":"Autoimmune Rheumatic Diseases","enrollment":200},{"nctId":"NCT05743595","phase":"PHASE1","title":"Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-27","conditions":"Unmethylated Glioblastoma","enrollment":27},{"nctId":"NCT02484417","phase":"PHASE1","title":"Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-21","conditions":"Upper Respiratory Tract Infection","enrollment":32},{"nctId":"NCT06059391","phase":"PHASE2","title":"CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-07-12","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia","enrollment":216},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT07340853","phase":"PHASE1","title":"CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2026-02-28","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06387511","phase":"NA","title":"Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months","status":"COMPLETED","sponsor":"Alliance for International Medical Action","startDate":"2024-05-07","conditions":"Immunization Coverage, Vaccination, Nutrition","enrollment":3814},{"nctId":"NCT06822881","phase":"PHASE1","title":"CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-02-20","conditions":"Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)","enrollment":27},{"nctId":"NCT06098690","phase":"NA","title":"Culturally Tailored HPV Psychoeducational Multimedia Intervention","status":"RECRUITING","sponsor":"University of Texas, El Paso","startDate":"2024-05-02","conditions":"Health Knowledge, Attitudes, Practice, Vaccine-Preventable Diseases, Intention","enrollment":63},{"nctId":"NCT07103148","phase":"PHASE3","title":"A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-11","conditions":"Yellow Fever Immunization","enrollment":2440},{"nctId":"NCT06805487","phase":"PHASE1","title":"Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-24","conditions":"Zika Virus","enrollment":27}],"_emaApprovals":[{"date":"","name":"Vaccination","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-29-06-30-00-3228191-en.pdf","date":"2026-04-07","type":"news","title":"[PDF] 2025: strong sales and EPS growth. Continued profitable ... - Sanofi","source":"www.sanofi.com"},{"url":"https://www.grandviewresearch.com/horizon/statistics/pharmaceutical-market/biologics-biosimilars-large-molecules/vaccines/global","date":"2026-04-07","type":"news","title":"Vaccines - Pharmaceutical market outlook - Grand View Research","source":"www.grandviewresearch.com"},{"url":"https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights?asPDF=1","date":"2026-04-07","type":"news","title":"[PDF] Novavax Reports Fourth Quarter and Full Year 2025 Financial ...","source":"ir.novavax.com"},{"url":"https://cdn.pfizer.com/pfizercom/product-pipeline/Q3_2025_Pipeline_Update_vFinal3.pdf?VersionId=j0yAmo1fKxX.kcUTn9R1ODCUnpnxgXQ4","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline","source":"cdn.pfizer.com"},{"url":"https://www.bmj.com/content/374/bmj.n2096","date":"2026-04-07","type":"news","title":"Covid-19: FDA approves Pfizer-BioNTech vaccine in record time","source":"www.bmj.com"}],"manufacturing":[{"role":"Manufacturer","site":"Newton Laboratories, Inc.","location":"","operator":"Newton Laboratories, Inc."}],"molecularData":{"oral":false,"chemblId":"CHEMBL2107962","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Oral"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"unii":"DL6OZ476V3","splId":"960fab85-6ea8-4799-bcd8-ac46fad57822","chemblId":"CHEMBL2107962"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":229137,"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 09:33:21.941812+00","atcClassification":{"source":"FDA openfda","atcCode":"","mechClass":"","pharmClass":"Standardized Insect Venom Allergenic Extract [EPC]"},"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: Post-Vaccination (Vaccination) by Pfizer**\n\nThe Post-Vaccination (Vaccination) by Pfizer is a vaccine that stimulates the body's adaptive immunity to prevent infectious diseases. As of 2025, the vaccine's revenue is not explicitly stated in the provided sources. However, Sanofi's vaccine sales decreased by 2.5% to €2.0 billion in 2025 [1]. This suggests that the vaccine's revenue may be declining, but the exact figure is unknown.\n\nThe competitive landscape for vaccines is highly competitive, with multiple players vying for market share. Novavax, for example, has announced a license agreement with Pfizer for use of Novavax's Matrix-M adjuvant technology in two infectious disease areas [3]. This agreement could potentially impact Pfizer's market share in the vaccine market. Additionally, Sanofi's Dupixent sales increased by 32.2% to €4.2 billion in 2025, indicating a strong presence in the market [1].\n\nKey upcoming catalysts for the vaccine market include patent cliffs, label expansions, and pipeline competitors. Sanofi has announced plans to execute a share buyback program in 2026 of €1 billion, which could impact the company's stock price and revenue [1]. Additionally, Novavax has announced plans to enter the clinic with its early-stage pipeline as early as 2027 [3]. This could potentially disrupt the market and impact Pfizer's revenue.\n\nThe market outlook for vaccines is expected to grow, with Sanofi expecting sales to grow by a high single-digit percentage at CER in 2026 [1]. However, the exact impact of the vaccine market on Pfizer's revenue is unknown due to limited data.","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.sanofi.com/assets/dotcom/pressreleases/2026/2026-01-29-06-30-00-3228191-en.pdf","date":"","title":"[PDF] 2025: strong sales and EPS growth. Continued profitable ... - Sanofi","source":"www.sanofi.com"},{"url":"https://www.grandviewresearch.com/horizon/statistics/pharmaceutical-market/biologics-biosimilars-large-molecules/vaccines/global","date":"","title":"Vaccines - Pharmaceutical market outlook - Grand View Research","source":"www.grandviewresearch.com"},{"url":"https://ir.novavax.com/press-releases/2026-02-26-Novavax-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights?asPDF=1","date":"","title":"[PDF] Novavax Reports Fourth Quarter and Full Year 2025 Financial ...","source":"ir.novavax.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[{"date":"2026 Mar 28","pmid":"41904562","title":"Cost-utility of pneumococcal strategies for adults aged 50 and older in Colombia: a model-based economic evaluation.","journal":"BMC health services research"},{"date":"2026 Mar 28","pmid":"41904223","title":"Non-propagating RNA virus-vectored HA/NA vaccine prevents shedding of antigen-drifted H1N1 influenza virus in pigs.","journal":"NPJ vaccines"},{"date":"2026 Mar 26","pmid":"41903669","title":"A circRNA Neoantigen Vaccine Elicits Potent Antitumor Immunity and Synergizes with Checkpoint Blockade in Melanoma.","journal":"Cancer letters"},{"date":"2026 Mar 27","pmid":"41903474","title":"Elevated body mass index is associated with delayed protective airway mucosal immune responses in mild SARS-CoV-2 infection.","journal":"EBioMedicine"},{"date":"2026 Mar 28","pmid":"41903103","title":"Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Thailand: Epidemiological Data Update.","journal":"Pulmonary therapy"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":21,"withResults":5},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:34:27.725637+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}